Valeant Pharmaceuticals International Inc. (NYSE:VRX)’s share price rose 5.3% on Wednesday . The company traded as high as $22.41 and last traded at $22.30, with a volume of 8,896,344 shares traded. The stock had previously closed at $21.17.

VRX has been the topic of a number of recent analyst reports. BMO Capital Markets began coverage on shares of Valeant Pharmaceuticals International in a research note on Tuesday, June 28th. They set a “market perform” rating and a $26.00 price target on the stock. Royal Bank Of Canada reissued a “sector perform” rating and issued a $65.00 target price on shares of Valeant Pharmaceuticals International in a research note on Monday, May 9th. JPMorgan Chase & Co. set a $35.00 target price on shares of Valeant Pharmaceuticals International and gave the company a “hold” rating in a research note on Monday, July 25th. Mizuho reissued an “underperform” rating and issued a $11.00 target price on shares of Valeant Pharmaceuticals International in a research note on Tuesday, July 26th. Finally, RBC Capital Markets reissued a “sector perform” rating and issued a $33.00 target price on shares of Valeant Pharmaceuticals International in a research note on Tuesday, July 19th. Seven equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $64.16.

The firm has a 50-day moving average of $22.27 and a 200-day moving average of $43.03. The stock’s market cap is $7.67 billion.

Valeant Pharmaceuticals International (NYSE:VRX) last posted its earnings results on Tuesday, June 7th. The specialty pharmaceutical company reported $1.27 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.37 by $0.10. The firm had revenue of $2.37 billion for the quarter, compared to analyst estimates of $2.34 billion. The business’s revenue was up 9.3% compared to the same quarter last year. During the same quarter last year, the firm posted $2.36 earnings per share. On average, analysts predict that Valeant Pharmaceuticals International Inc. will post $6.55 EPS for the current year.

In other news, CEO Joseph C. Papa bought 202,000 shares of the stock in a transaction dated Friday, June 10th. The shares were acquired at an average price of $24.48 per share, with a total value of $4,944,960.00. Following the acquisition, the chief executive officer now owns 2,442,199 shares in the company, valued at $59,785,031.52. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Several large investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP raised its stake in Valeant Pharmaceuticals International by 3.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 79,777 shares of the specialty pharmaceutical company’s stock valued at $8,110,000 after buying an additional 2,500 shares during the last quarter. Deere & Co. raised its stake in Valeant Pharmaceuticals International by 121.1% in the fourth quarter. Deere & Co. now owns 15,011 shares of the specialty pharmaceutical company’s stock valued at $1,526,000 after buying an additional 8,222 shares during the last quarter. Napier Park Global Capital US LP purchased a new stake in Valeant Pharmaceuticals International during the fourth quarter valued at $1,740,000. Atlantic Trust Group LLC raised its stake in Valeant Pharmaceuticals International by 79.7% in the fourth quarter. Atlantic Trust Group LLC now owns 40,283 shares of the specialty pharmaceutical company’s stock valued at $4,095,000 after buying an additional 17,868 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D purchased a new stake in Valeant Pharmaceuticals International during the fourth quarter valued at $2,033,000.

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.